Biote Sees FY26 Revenue Over $190M
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy BTMD?
Biote sees FY26 revenue over $190M, consensus $191.7M
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BTMD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BTMD
About BTMD
biote Corp. operates a practice-building business within the hormone optimization space. The Company provides the necessary components to enable Biote-certified practitioners to establish, build and implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The Biote Method is a comprehensive, end-to-end practice building platform that provides Biote-certified practitioners with the components specifically developed for practitioners in the hormone optimization space: Biote Method education, training and certification, practice management software, inventory management software, and information regarding available hormone replacement therapy (HRT) products, as well as digital and point-of-care marketing support. It also sells a complementary Biote-branded line of dietary supplements. The Biote Method’s proprietary clinical decision support (CDS) software assists physicians in establishing individualized dosing for patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Biote (BTMD) Q1 2026 Earnings Call Insights
- Performance Pressure: Biote reported Q1 2026 revenue of $44.9 million, an 8.3% decline year-over-year, with procedure revenue down 13.2% to $31.3 million, primarily impacted by a voluntary recall that resulted in an estimated $1.7 million revenue loss, placing significant financial pressure on the company.
- Sales Team Expansion: Despite the recall challenges, Biote successfully hired 25 new sales personnel and trained over 200 new practitioners in Q1, representing a 16.5% increase from Q1 2025, demonstrating the company's ongoing efforts to enhance market competitiveness.
- Maintained Outlook: CFO Peterson reiterated the full-year revenue target of over $190 million and adjusted EBITDA exceeding $38 million, acknowledging a downward adjustment in first-half procedure revenue expectations, yet remaining optimistic about recovery in the second half of the year.
- Ongoing Recall Impact: Management noted that the recall has distracted the sales team from focusing on growth objectives, with expectations that this impact will continue into Q2; however, they believe it is a temporary issue that will not affect their long-term strategy.
See More
Biote Corp. Q4 2025 Earnings Call Insights
- Sales Team Expansion: Biote Corp. reported that its sales team grew to over 90 members by the end of 2025, up from 60 prior to the reorganization, successfully stabilizing clinic attrition and maximizing new clinic starts, indicating positive progress in rebuilding its commercial team.
- Financial Performance Overview: The fourth quarter revenue was $46.4 million, with procedure revenue declining 13% to $31.8 million, while dietary supplement revenue grew 16% to $11.7 million, providing a new revenue stream despite the overall decline in revenue.
- Future Outlook: The company forecasts revenues exceeding $190 million and adjusted EBITDA above $38 million for 2026, with a projected decline in procedure revenue in the first half but anticipated growth in the second half, reflecting management's cautious optimism about future performance.
- Investments and Expenses: Management plans to increase sales personnel to approximately 120 in 2026 and make significant investments in the technology platform, which will lead to a near-term rise in operating expenses but is expected to lay the groundwork for future growth in procedure revenue.
See More
BIOTE Releases Financial Outlook for 2026
- Earnings Highlights: BIOTE's Q4 GAAP EPS of $0.06 exceeded expectations by $0.04, while revenue of $46.4 million, despite a 6.9% year-over-year decline, beat estimates by $0.61 million, demonstrating the company's resilience in challenging conditions.
- 2026 Revenue Outlook: The company anticipates total revenue exceeding $190 million in 2026, with procedure revenue expected to decline at a mid to high single-digit percentage rate in the first half, but projected to return to growth in the second half, indicating potential market recovery.
- Adjusted EBITDA Guidance: BIOTE expects adjusted EBITDA to exceed $38 million in 2026, reflecting ongoing efforts in cost control and operational efficiency aimed at enhancing profitability and boosting investor confidence.
- Nutritional Supplements Growth: Revenue from dietary supplements is expected to grow at a mid to high single-digit rate in 2026, indicating the company's strong positioning in the health and nutrition sector to capitalize on the increasing consumer demand for health products.
See More
Biote Corp Reports Decrease in Q3 Earnings
- Earnings Decline: biote Corp reported a third-quarter profit of $8.19 million, down from $10.70 million in the same period last year.
- Earnings Per Share: The earnings per share (EPS) decreased to $0.22 from $0.33 year-over-year.
- Revenue Drop: The company's revenue fell by 6.7% to $47.96 million, compared to $51.38 million in the previous year.
- Financial Overview: Key financial metrics indicate a decline in both earnings and revenue for biote Corp compared to the prior year.
See More
Capricor (CAPR) Rises 5.3%: Could This Signal More Upside Ahead?
Capricor Therapeutics Stock Performance: Capricor Therapeutics (CAPR) shares rose 5.3% to $6.52, driven by a positive regulatory update on its Deramiocel program for Duchenne muscular dystrophy, which may expedite the drug's market entry.
Earnings Expectations and Market Position: The company is projected to report a quarterly loss of $0.54 per share, with revenues expected to increase by 6.2% year-over-year. The consensus EPS estimate has remained stable, indicating potential stock price movements may depend on future earnings revisions.
See More
Biote Names Rich Barrera to Board of Directors
New Board Member Announcement: Biote Corp. has appointed Rich Barrera to its Board of Directors, bringing over 20 years of investment management experience and alignment with the company's growth strategy.
Company Overview: Biote focuses on preventive health care through personalized hormone optimization and wellness solutions, aiming to address aging conditions and enhance clinic success for practitioners.
See More
Biote (BTMD) Q1 2026 Earnings Call Insights
- Performance Pressure: Biote reported Q1 2026 revenue of $44.9 million, an 8.3% decline year-over-year, with procedure revenue down 13.2% to $31.3 million, primarily impacted by a voluntary recall that resulted in an estimated $1.7 million revenue loss, placing significant financial pressure on the company.
- Sales Team Expansion: Despite the recall challenges, Biote successfully hired 25 new sales personnel and trained over 200 new practitioners in Q1, representing a 16.5% increase from Q1 2025, demonstrating the company's ongoing efforts to enhance market competitiveness.
- Maintained Outlook: CFO Peterson reiterated the full-year revenue target of over $190 million and adjusted EBITDA exceeding $38 million, acknowledging a downward adjustment in first-half procedure revenue expectations, yet remaining optimistic about recovery in the second half of the year.
- Ongoing Recall Impact: Management noted that the recall has distracted the sales team from focusing on growth objectives, with expectations that this impact will continue into Q2; however, they believe it is a temporary issue that will not affect their long-term strategy.
See More
Biote Corp. Q4 2025 Earnings Call Insights
- Sales Team Expansion: Biote Corp. reported that its sales team grew to over 90 members by the end of 2025, up from 60 prior to the reorganization, successfully stabilizing clinic attrition and maximizing new clinic starts, indicating positive progress in rebuilding its commercial team.
- Financial Performance Overview: The fourth quarter revenue was $46.4 million, with procedure revenue declining 13% to $31.8 million, while dietary supplement revenue grew 16% to $11.7 million, providing a new revenue stream despite the overall decline in revenue.
- Future Outlook: The company forecasts revenues exceeding $190 million and adjusted EBITDA above $38 million for 2026, with a projected decline in procedure revenue in the first half but anticipated growth in the second half, reflecting management's cautious optimism about future performance.
- Investments and Expenses: Management plans to increase sales personnel to approximately 120 in 2026 and make significant investments in the technology platform, which will lead to a near-term rise in operating expenses but is expected to lay the groundwork for future growth in procedure revenue.
See More
BIOTE Releases Financial Outlook for 2026
- Earnings Highlights: BIOTE's Q4 GAAP EPS of $0.06 exceeded expectations by $0.04, while revenue of $46.4 million, despite a 6.9% year-over-year decline, beat estimates by $0.61 million, demonstrating the company's resilience in challenging conditions.
- 2026 Revenue Outlook: The company anticipates total revenue exceeding $190 million in 2026, with procedure revenue expected to decline at a mid to high single-digit percentage rate in the first half, but projected to return to growth in the second half, indicating potential market recovery.
- Adjusted EBITDA Guidance: BIOTE expects adjusted EBITDA to exceed $38 million in 2026, reflecting ongoing efforts in cost control and operational efficiency aimed at enhancing profitability and boosting investor confidence.
- Nutritional Supplements Growth: Revenue from dietary supplements is expected to grow at a mid to high single-digit rate in 2026, indicating the company's strong positioning in the health and nutrition sector to capitalize on the increasing consumer demand for health products.
See More
Biote Corp Reports Decrease in Q3 Earnings
- Earnings Decline: biote Corp reported a third-quarter profit of $8.19 million, down from $10.70 million in the same period last year.
- Earnings Per Share: The earnings per share (EPS) decreased to $0.22 from $0.33 year-over-year.
- Revenue Drop: The company's revenue fell by 6.7% to $47.96 million, compared to $51.38 million in the previous year.
- Financial Overview: Key financial metrics indicate a decline in both earnings and revenue for biote Corp compared to the prior year.
See More
Capricor (CAPR) Rises 5.3%: Could This Signal More Upside Ahead?
Capricor Therapeutics Stock Performance: Capricor Therapeutics (CAPR) shares rose 5.3% to $6.52, driven by a positive regulatory update on its Deramiocel program for Duchenne muscular dystrophy, which may expedite the drug's market entry.
Earnings Expectations and Market Position: The company is projected to report a quarterly loss of $0.54 per share, with revenues expected to increase by 6.2% year-over-year. The consensus EPS estimate has remained stable, indicating potential stock price movements may depend on future earnings revisions.
See More
Biote Names Rich Barrera to Board of Directors
New Board Member Announcement: Biote Corp. has appointed Rich Barrera to its Board of Directors, bringing over 20 years of investment management experience and alignment with the company's growth strategy.
Company Overview: Biote focuses on preventive health care through personalized hormone optimization and wellness solutions, aiming to address aging conditions and enhance clinic success for practitioners.
See More
